secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001104659-23-113576
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics Q3 net loss $49.9M; FDA aligns on BT8009 Phase 2/3 trial for bladder cancer
--------------------------------------------------------------------------------

- Net loss $49.9M ($1.26/share) vs $28.3M ($0.96/share) in Q3 2022; R&D expenses rose to $39.9M.
- Cash $572.1M as of Sep 30, 2023, up from $339.2M at Dec 31, 2022, including $215.1M net from July offering.
- FDA aligned on Phase 2/3 registrational trial (Duravelo-2) for BT8009 in metastatic bladder cancer; starts Q1 2024.
- BT8009 selected for FDA's CMC Development and Readiness Pilot (CDRP) program to expedite manufacturing.
- Company plans R&D Day on Dec 14, 2023, to provide updates on BT8009, BT5528, and BT7480.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465923113576/0001104659-23-113576-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465923113576/tm2329595d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-113576

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer